Akebia Therapeut Stock Price, News & Analysis

Akebia Therapeutics (NASDAQ: AKBA) announced significant business updates regarding Vafseo® (vadadustat), its treatment for anemia in chronic kidney disease (CKD) patients on dialysis. The company has secured commercial supply contracts covering nearly 100% of U.S. dialysis patients and commenced product shipments in January 2025.

Market research indicates strong physician interest, with 99% of nephrologists considering prescribing Vafseo and 75% planning to do so within 6 months. The company plans to expand Vafseo's label through a Phase 3 trial for non-dialysis CKD patients, starting mid-2025, targeting a potential billion-dollar market opportunity.

U.S. Renal Care has enrolled over 650 patients in the VOICE clinical trial. Akebia confirms its current cash resources will fund operations, including the U.S. launch and pipeline development, for at least two years.

Akebia Therapeutics (AKBA) has granted stock options to one newly-hired employee as part of their employment inducement package. The grant, issued on December 31, 2024, consists of options to purchase 3,000 shares of Akebia's common stock at an exercise price of $1.90 per share, matching the closing price on the grant date.

The options feature a four-year vesting schedule, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. The options have a 10-year term and are subject to Akebia's inducement award program terms. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4).

Akebia Therapeutics (Nasdaq: AKBA) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO John Butler will deliver a presentation on Thursday, January 16, 2024, at 7:30 AM PST, which will include updates on the Vafseo® (vadadustat) U.S. launch and other business matters. The conference is scheduled for January 13-16, 2025, in San Francisco. Interested parties can access the presentation webcast through the 'Investors' section of Akebia's website after the conference.

Akebia Therapeutics (Nasdaq: AKBA) has granted stock options to nine newly-hired employees on November 29, 2024. The inducement grants total 121,000 shares of common stock with an exercise price of $2.06 per share, matching the closing price on the grant date. The options follow a four-year vesting schedule with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. These 10-year term options were granted under Nasdaq Listing Rule 5635(c)(4) as part of Akebia's inducement award program.

Akebia Therapeutics (Nasdaq: AKBA) announced that U.S. Renal Care has enrolled the first patients in the VOICE collaborative trial for Vafseo (vadadustat). The study will evaluate Vafseo's safety and efficacy when administered three times weekly to dialysis patients, comparing it to standard-of-care treatments. The trial aims to enroll approximately 2,200 patients and will assess non-inferiority for all-cause mortality as primary endpoint and superiority in reducing all-cause hospitalization as secondary endpoint. Vafseo, approved by the FDA in March 2024 for anemia in CKD patients on dialysis, is expected to launch in January 2025.

Akebia Therapeutics (Nasdaq: AKBA) announced its participation in the 36th Annual Piper Sandler Healthcare Conference. CEO John Butler will lead a Fireside Discussion on December 3rd at 10:30 AM EST. The conference is scheduled for December 3-5, 2024 in New York. A webcast of the presentation will be available on Akebia's investor relations website for six months following the event. Akebia focuses on developing treatments for people affected by kidney disease.

Akebia Therapeutics (Nasdaq: AKBA) announced the publication of FO2CUS trial results in the American Journal of Kidney Disease, evaluating Vafseo® (vadadustat) for anemia treatment in hemodialysis patients. The study compared three-times-weekly oral vadadustat dosing to long-acting ESA in 456 patients. Vafseo®, approved by FDA in March 2024 for anemia treatment in chronic kidney disease patients on dialysis, is scheduled for U.S. launch in January 2025. The study examined 600mg and 900mg vadadustat doses versus Mircera®, measuring hemoglobin changes at weeks 20-26 and 46-52.

Akebia Therapeutics (Nasdaq: AKBA) has announced its participation in the upcoming Jefferies London Healthcare Conference. CEO John Butler will deliver a presentation on Thursday, November 21 at 1:00 PM GMT. The conference is scheduled for November 19-21, 2024, in London. Interested parties can access the presentation webcast through the 'Investors' section of Akebia's website at ir.akebia.com, where it will remain available for 30 days after the event. Akebia Therapeutics focuses on improving the lives of people affected by kidney disease.

Akebia Therapeutics reported its Q3 2024 financial results and recent business highlights. Key points include the commercial launch of Vafseo® (vadadustat) expected in January 2025. Approximately 60% of U.S. dialysis patients are now covered under contracts for Vafseo. The drug has been granted TDAPA reimbursement and a Level II Healthcare Common Procedure Coding System code. Akebia also partnered with U.S. Renal Care for a trial to evaluate Vafseo's outcomes in dialysis patients.

Financially, Akebia reported total revenues of $37.4 million, down from $42.0 million in Q3 2023. Net product revenues for Auryxia were $35.6 million, down from $40.1 million. The cost of goods sold decreased to $14.2 million from $18.0 million. R&D expenses fell to $8.5 million from $13.3 million, while SG&A expenses rose to $26.5 million from $22.7 million. Akebia's net loss increased to $20.0 million from $14.5 million. The company had $34.0 million in cash and cash equivalents as of September 30, 2024.